Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: The Saint who wrote (1516)	11/9/1998 10:13:00 PM
From: Bald Man from Mars	Read Replies (1) \| Respond to of 3576

<< I will be watching you!>> you are scaring me, are you a stalker ... is your binocular powerful enough ???

To: The Saint who wrote (1516)	11/9/1998 10:44:00 PM
From: Robert	Read Replies (1) \| Respond to of 3576

Saint, I hope your name means you can perform miracles. That's what you'll need if you expect to get to 35-40 in 1-2 weeks. Sometimes you gotta admit to yourself that you made a mistake. Here's a few reminders from the releases: It is not unusual for biotech companies to fly high on research advances -- and heavy media play that accompanies such reports -- before retreating on the realization that any profits may come far in the future. EntreMed, a Rockville, Md. biotech firm, saw its shares skyrocket from $12 to $85 within a day after media reports that two of its drugs might lead to a cancer cure. When investors realized no such cure existed today, and the company was still years away from putting its research into practical use, the shares quickly fell back to $27 later in May. Geron executives on Friday acknowledged they are at least five to 10 years away from developing stem cells for human transplant purposes. That's if they can do it all. Biotech analysts acknowledge that Geron's research findings signal a major scientific step forward. But they say Wall Street overreacted -- again. ''The reaction of the stock price is absurd,'' said Jim McCamant, editor of the Medical Technology Stock Letter in Berkeley, Calif. Robert...